buysid read top
note juli miss
juli alzheim ep preview filgotinib preview
neulasta biosimilar doc check biotech video among read
report buysid rest top insid tabl link
select rank-ord note jefferi biotech team addit
highlight report ticker analyst uniqu insight
differenti view revisit
posit alzheim data help hypothesi aducanumab jul
bull/bear set-up look like jul
phase filgotinib ra data come anoth driver turnaround jul
industri new guidanc document gt increment posit industri jul
comment alzheim data week jul
industri potenti news celg gilenya gener delay jul
neulasta biosimilar check doc say primari driver level rebat jul
data debat stand question jul
industri video know go earn year jul
eun yang key report dova us hematologist poll point
rapid tavaliss uptak like upsid current estim
survey particularli interest light recent market sell-off launch
suggest launch especi medium term go well addit held
investor meet dova report doptelet launch
initi indic progress expans addit market opportun
biren amin key report autl report key take
retin specialist call ladder top-line data asr wamd therapeut
landscap although there challeng adopt think roch port deliveri
pd lucenti look increasingli competit eylea wamd
initi coverag autl juli buy rate pt autl
develop broad array next-gen car-t therapi heme malign solid
tumor co robust pipelin center innov would potenti
address issu car-t safeti durabl relaps autl five clinic stage
asset start produc data catalyst
matthew andrew key report industri follow promis er
mbc data present acso updat model includ
indic probabl success plan meet fda discuss
regulatory/clin pathway forward program come month rais pt
expect fda accept bla mtnbc
pdufa data prioriti review updat hem/onc btd analysi
suggest vs prior chanc approv average review timelin origin
btd ndas/bla remain day approv could arriv mid-nov
mauri raycroft key report preview major
catalyst -- retain benefit analysi ph ii alport syndrom trial result
posit de-risk path acceler approv on-going ph iii well
adpkd oppti updat po program accordingli
discuss anoth scienc public use experiment system view
limit repres current gene-edit strategi approach clinic
therefor though public remind safeti vigil need believ
conclus drawn public applic initi recent
ipod believ immun proteasom inhibitor program potenti rang
autoimmun indic somewhat de-risk success gener proteasom
inhibitor oncolog
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
exhibit list select note publish jefferi biotech team sort hit continu next page
posit alzheim data help hypothesi aducanumab
bull/bear set-up look like
phase filgotinib ra data come anoth driver turnaround buy
new guidanc document gt increment posit industri
comment alzheim data week higher probabl aducanumab
potenti news celg possibl gilenya gener delay
neulasta biosimilar check doc say primari driver level rebat
data debat stand question
video know go earn year
neulasta biosimilar price discount rebat still open question
addit news luspatercept help build confid pipelin
new gilead come turnaround new ceo take rein
ban data also gener somewhat in-lin w/ high expect
nv interest notabl read-through
rais pt acceler tripl cf data nda file come sooner
increment good news time revlimid
new hemophilia data isth pot updat ep day thought
anoth gene therapi in-licens program ad new orphan muscl dystrophi
video know month lot lot go come
commentari kol well-known dr nissen suggest major concern safeti
video need know minut
posit thesi unfold money-flow come get closer
major surpris gsk hiv data think continu turn year
alzheim panel confer call preview week
strong kick biotech earn season posit note
recent develop sector sentiment rotat
interest thing conf min summar sec
chart look scriptsamgn vs
steadi goe guidanc look conserv pt increas
merck other grow interest tgf-b cancer add valu
thing conf call minut summar second
new management new gene therapi drug import data come
slowli claw back time solid quarter in-lin w/ thesi
strong beat guidanc rais exec chang neutral surpris
model chang post-asco data fda respons bla soon
competitor myostatin drug show datapoint increas muscl mass
bla accept updat btd analysi suggest likelihood approv
initi buy selectivity/profil may open vast autoimmun market
vicinium promis aggress bladder cancer initi buy pt
ph success rolonti set stage bla submiss
page
pleas see import disclosur inform page report
exhibit list select note publish jefferi biotech team sort hit
triple-plan track buyer growth trajectori come buy
studi continu chang increment surpris
chmp opinion may readthrough label content strategi
quarter move closer closer data
hematologist poll point greater tavaliss potenti vs current expect
biotech short interest market cap
pacritinib updat ph need delay maintain buy pt lower
w/ management -- ome back -- readout potenti opt-in
txcell acquisit bring immunolog capabl mp ii mp advanc
updat investor meet dova manag
updat investor meet manag
updat investor meet manag
biotech short interest market cap
updat investor meet arri manag
ep larg lower d/slightli higher revenu
page
pleas see import disclosur inform page report
